ALLOSTERIC MODULATION
We’re a talented group of scientists and entrepreneurs with a groundbreaking ability to 'see' and characterize new functional allosteric binding sites on proteins for drug development.
Our proprietary hydrogen-deuterium exchange LC-MS/MS (fastHDX™) can take soluble proteins of interest and map out remote (allosteric) binding sites capable of actually modulating the active (orthosteric) site and rapidly deliver early allosteric hits against molecular targets with high target selectivity.
OUR TECHNOLOGY
Our proprietary fastHD approach, based on 50 years experience in high speed liquid exchange, enables us to see quickly the effects of low affinity allosteric binding typical of the early hits generated in fragment-based drug design programmes.
EXECUTIVE TEAM
DR LINDSAY COLE
Director & CSO
DR JOHN NORMANTON
Director & CEO
DR JJ PHILLIPS
Director & Scientific Consultant
DR TIM FLANAGAN
Chairman
DR GERRY RONAN
Non-Executive Director